Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 17 Jun 2021
Furore rages over FDA approval of controversial Alzheimer’s drug
17 June 2021 - Critics attack the agency’s action as reckless, but defenders say patients will benefit. ...
Posted by Michael Wonder on 17 Jun 2021
Dupixent (dupilumab) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
17 June 2021 - The pre-filled pen offers an additional administration option for all Dupixent indications in patients aged 12 years ...
Posted by Michael Wonder on 17 Jun 2021
Vaccine confusion as clots force jab switch for two million
17 June 2021 - Health authorities are scrambling to switch more than two million Australians aged under 60 to the ...
Posted by Michael Wonder on 17 Jun 2021
The FDA is in desperate need of some soul-searching
17 June 2021 - Ordinarily, the approval of a new drug for a dreaded disease affecting millions of Americans would be ...
Posted by Michael Wonder on 17 Jun 2021
Amneal announces U.S. FDA filing acceptance of biologics license application for bevacizumab
17 June 2021 - Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA. ...
Posted by Michael Wonder on 17 Jun 2021
Agenus announces U.S. FDA acceptance and priority review of balstilimab biologics license application for the treatment of recurrent or metastatic cervical cancer
17 June 2021 - Agenus today announced that the U.S. FDA has accepted Agenus’ biologics license application for balstilimab, an ...
Posted by Michael Wonder on 17 Jun 2021
FDA approves a nasal anti-histamine for non-prescription use
17 June 2021 - The U.S. FDA today approved a nasal antihistamine for nonprescription use through a process called a partial ...
Posted by Michael Wonder on 17 Jun 2021
Applied Therapeutics granted fast track designation by FDA for AT-007 for galactosaemia
17 June 2021 - Applied Therapeutics today announced that the U.S. FDA has granted fast track designation to AT-007 for the ...
Posted by Michael Wonder on 17 Jun 2021
Shared decision making underpins good health care
17 June 2021 - Shared decision making between service users and health care professionals is an integral part of health care, ...
Posted by Michael Wonder on 17 Jun 2021
A life-saving new drug for COVID-19 is found
16 June 2021 - But only rich countries will benefit, and even they will struggle to get hold of it. ...
Posted by Michael Wonder on 17 Jun 2021
Eagle Pharmaceuticals submits response to complete response letter from FDA for vasopressin
17 June 2021 - Eagle Pharmaceuticals today announced that it has responded to the complete response letter for its abbreviated ...
Posted by Michael Wonder on 17 Jun 2021
Ontozry scores MHRA authorisation for focal-onset seizures
17 June 2021 - The MHRA has granted Arvelle Therapeutics’ Ontozry a marketing authorisation for the adjunctive treatment of focal-onset ...
Posted by Michael Wonder on 17 Jun 2021
Statement in response to latest ATAGI advice regarding COVID-19 vaccines
17 June 2021 - A statement from the Professor Paul Kelly, Australian Government Chief Medical Officer in response to the latest ...
Posted by Michael Wonder on 17 Jun 2021
U.S. Government purchases additional 200 million doses of Moderna’s COVID-19 vaccine
16 June 2021 - Total of 500 million doses ordered by the U.S government to date, including 110 million doses for ...
Posted by Michael Wonder on 17 Jun 2021
Expanded PBS listing to save Australians around $120,000 a year
17 June 2021 - More than 800 Australians with stage IV advanced or metastatic kidney cancer will now have improved access ...